PMID- 37891683
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231030
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 15
IP  - 1
DP  - 2023 Oct 28
TI  - Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes 
      patients: an updated systematic review and meta-analysis.
PG  - 218
LID - 10.1186/s13098-023-01195-7 [doi]
LID - 218
AB  - OBJECTIVES: To update and assess the efficacy and tolerability of once weekly 
      subcutaneous semaglutide in patients with type 2 diabetes (T2D). MATERIALS AND 
      METHODS: PubMed, Science Direct, Cochrane Library, Clinical trial, Springer, 
      OVID, China National Knowledge Infrastructure (CNKI), WanFang Data and China 
      Science and Technology Journal Database (VIP) were searched from inception to 
      January 18, 2023. Randomized controlled trials (RCTs) comparing subcutaneous 
      semaglutide with placebo or any other antidiabetic agent in adults with T2D were 
      eligible. The risk ratio (RR) and mean difference (MD) with 95% confidence 
      intervals (CIs) were determined to synthesize the results. RESULTS: A total of 17 
      trials enrolling 14,940 T2D patients were included. For efficacy, compared with 
      placebo, semaglutide exhibited beneficial effects on glycosylated hemoglobin A1c 
      (HbA1c) control [MD -0.97%, 95% CI (-1.33, -0.62), I(2) = 91%; MD -1.36%, 95% CI 
      (-1.59, -1.13), I(2) = 84%, semaglutide 0.5 and 1.0 mg, respectively], body 
      weight reduction, blood pressure control. At the same time, subcutaneous 
      semaglutide 0.5 and 1 mg reduced HbA(1c) by 0.56% (95% CI 0.32 to 0.80) and 0.63% 
      (95% CI 0.35 to 0.91) compared to other glucose-lowering agents. For 
      tolerability, semaglutide did not increase the incidence of adverse events (AEs) 
      and serious adverse events (SAEs), severe or blood glucose (BG) confirmed 
      hypoglycaemia, acute pancreatitis and diabetic retinopathy compared to placebo or 
      active comparators, but did increase the risk of nausea, diarrhea and vomiting. 
      CONCLUSIONS: Semaglutide has a better effect on glycaemic control and weight loss 
      than other therapies. Nevertheless, semaglutide was associated with increased 
      incidence of gastrointestinal-related disorders. Further large, multicenter 
      randomized controlled clinical trials are still needed to obtain more robust 
      evidence to better guide clinical treatment decisions.
CI  - (c) 2023. The Author(s).
FAU - Hu, Shanshan
AU  - Hu S
AD  - Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, 200080, China.
FAU - Su, Xiaorong
AU  - Su X
AD  - Department of Pharmacy, Xiamen Maternal and Child Health Hospital, Xiamen, 
      361003, China.
FAU - Fan, Guorong
AU  - Fan G
AD  - Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, 200080, China. guorfan@163.com.
LA  - eng
GR  - Z-2021-46-2101/the Research Fund for Clinical Pharmacy of China International 
      Medical Foundation/
GR  - 81973289/National Natural Science Foundation of China/
PT  - Journal Article
PT  - Review
DEP - 20231028
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC10612199
OTO - NOTNLM
OT  - Meta-analysis
OT  - Randomized controlled trials
OT  - Semaglutide
OT  - Type 2 Diabetes
COIS- The authors declare no competing interests.
EDAT- 2023/10/28 11:48
MHDA- 2023/10/28 11:49
PMCR- 2023/10/28
CRDT- 2023/10/27 23:58
PHST- 2023/07/11 00:00 [received]
PHST- 2023/10/17 00:00 [accepted]
PHST- 2023/10/28 11:49 [medline]
PHST- 2023/10/28 11:48 [pubmed]
PHST- 2023/10/27 23:58 [entrez]
PHST- 2023/10/28 00:00 [pmc-release]
AID - 10.1186/s13098-023-01195-7 [pii]
AID - 1195 [pii]
AID - 10.1186/s13098-023-01195-7 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2023 Oct 28;15(1):218. doi: 10.1186/s13098-023-01195-7.